Table of Contents
1. Executive summary
2. Market Introduction
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. Research Methodology
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. Market Dynamics
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. Market Factor Analysis
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL Clinical genomics MARKET, BY Test Type
6.1. Overview
6.2. Diagnostic Testing
6.3. Genetic Testing
6.4. Newborn Screening
6.5. Preimplantation Testing
6.6. Prenatal Testing
6.7. Carrier Testing
6.8. Other Tests
7. GLOBAL Clinical genomics MARKET, BY Method
7.1. Overview
7.2. Molecular Tests
7.3. Chromosomal Tests
7.4. Biochemical Tests
8. GLOBAL Clinical genomics MARKET, BY End User
8.1. Overview
8.2. Hospitals & Clinics
8.3. Government Laboratories & Research Centres
8.4. Academics and Research Institutes
8.5. Other End Users
9. GLOBAL Clinical genomics MARKET, by Region
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. South Korea
9.4.5. Australia
9.4.6. Rest of Asia-Pacific
9.5. Rest of the World
9.5.1. Middle East
9.5.2. Africa
9.5.3. Latin America
10. Competitive Landscape
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Clinical genomics Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Clinical genomics Market,
10.7. Key developments and Growth Strategies
10.7.1. New Test Type Launch/Method Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2022
10.8.2. Major Players R&D Expenditure. 2022
11. Company ProfileS
11.1. Clinical genomics marketare Quest Diagnostics Incorporated (U.S.).
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Test Types Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Eurofins Scientific SE (Luxembourg)
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Test Types Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. Illumina, Inc. (U.S.)
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Test Types Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. PerkinElmer, Inc. (U.S.)
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Test Types Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. NeoGenomics Inc. (U.S.)
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Test Types Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. FOUNDATION MEDICINE, INC. (U.S.).
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Test Types Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Rosetta Genomics Ltd. (Israel)
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Test Types Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Invitae Corporation (U.S.)
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Test Types Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Myriad Genetics, Inc. (U.S.)
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Test Types Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Natera, Inc. (U.S.)
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Test Types Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Genomic Health, Inc. (U.S.)
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Test Types Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
11.12. OPKO Health, Inc. (U.S.)
11.12.1. Company Overview
11.12.2. Financial Overview
11.12.3. Test Types Offered
11.12.4. Key Developments
11.12.5. SWOT Analysis
11.12.6. Key Strategies
11.13. Centogene AG (Germany)
11.13.1. Company Overview
11.13.2. Financial Overview
11.13.3. Test Types Offered
11.13.4. Key Developments
11.13.5. SWOT Analysis
11.13.6. Key Strategies
11.14. Clinical Genomics Pty Ltd. (Australia)
11.14.1. Company Overview
11.14.2. Financial Overview
11.14.3. Test Types Offered
11.14.4. Key Developments
11.14.5. SWOT Analysis
11.14.6. Key Strategies
11.15. 23andMe, Inc. (U.S.)
11.15.1. Company Overview
11.15.2. Financial Overview
11.15.3. Test Types Offered
11.15.4. Key Developments
11.15.5. SWOT Analysis
11.15.6. Key Strategies
11.16. Iverson Genetic Diagnostics, Inc. (U.S.)
11.16.1. Company Overview
11.16.2. Financial Overview
11.16.3. Test Types Offered
11.16.4. Key Developments
11.16.5. SWOT Analysis
11.16.6. Key Strategies
11.17. Veritas Genetics (U.S.)
11.17.1. Company Overview
11.17.2. Financial Overview
11.17.3. Test Types Offered
11.17.4. Key Developments
11.17.5. SWOT Analysis
11.17.6. Key Strategies
11.18. Gene by Gene, Ltd. (U.S.)
11.18.1. Company Overview
11.18.2. Financial Overview
11.18.3. Test Types Offered
11.18.4. Key Developments
11.18.5. SWOT Analysis
11.18.6. Key Strategies
11.19. GenomeDx Biosciences, Inc. (Canada)
11.19.1. Company Overview
11.19.2. Financial Overview
11.19.3. Test Types Offered
11.19.4. Key Developments
11.19.5. SWOT Analysis
11.19.6. Key Strategies
11.20. MedGenome (India)
11.20.1. Company Overview
11.20.2. Financial Overview
11.20.3. Test Types Offered
11.20.4. Key Developments
11.20.5. SWOT Analysis
11.20.6. Key Strategies
11.21. Strand Life Sciences Pvt. Ltd. (India)
11.21.1. Company Overview
11.21.2. Financial Overview
11.21.3. Test Types Offered
11.21.4. Key Developments
11.21.5. SWOT Analysis
11.21.6. Key Strategies
11.22. Beijing Genomics Institute (BGI) (China)
11.22.1. Company Overview
11.22.2. Financial Overview
11.22.3. Test Types Offered
11.22.4. Key Developments
11.22.5. SWOT Analysis
11.22.6. Key Strategies
11.23. Retrogen, Inc. (U.S.)
11.23.1. Company Overview
11.23.2. Financial Overview
11.23.3. Test Types Offered
11.23.4. Key Developments
11.23.5. SWOT Analysis
11.23.6. Key Strategies
11.24. Personalis, Inc. (U.S.)
11.24.1. Company Overview
11.24.2. Financial Overview
11.24.3. Test Types Offered
11.24.4. Key Developments
11.24.5. SWOT Analysis
11.24.6. Key Strategies
11.25. PathGroup (U.S.)
11.25.1. Company Overview
11.25.2. Financial Overview
11.25.3. Test Types Offered
11.25.4. Key Developments
11.25.5. SWOT Analysis
11.25.6. Key Strategies
12. Appendix
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 Global Clinical genomics Market, Synopsis, 2018-2032
TABLE 2 Global Clinical genomics Market, Estimates & Forecast, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 5 GLOBAL Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 6 North America Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 7 North America Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 8 North America Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 9 North America Clinical genomics MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 10 U.S. Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 11 U.S. Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 12 U.S. Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 13 Canada Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 14 Canada Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 15 Canada Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 16 Europe Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 17 Europe Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 18 Europe Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 19 Europe Clinical genomics MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 20 Germany Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 21 Germany Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 22 Germany Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 23 France Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 24 France Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 25 France Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 26 Italy Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 27 Italy Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 28 Italy Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 29 Spain Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 30 Spain Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 31 Spain Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 32 U.K Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 33 U.K Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 34 U.K Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 35 Rest of Europe Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 36 Rest of Europe Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 37 Rest of Europe Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 38 Asia Pacific Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 39 Asia Pacific Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 40 Asia Pacific Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 41 Asia Pacific Clinical genomics MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 42 Japan Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 43 Japan Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 44 Japan Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 45 China Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 46 China Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 47 China Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 48 India Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 49 India Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 50 India Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 51 Australia Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 52 Australia Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 53 Australia Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 54 south korea Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 55 south korea Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 56 south korea Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 57 Rest of asia-pacific Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 58 Rest of asia-pacific Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 59 Rest of asia-pacific Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 60 Rest of WOrld Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 61 Rest of WOrld Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 62 Rest of WOrld Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 63 Rest of WOrld Clinical genomics MARKET, BY Country, 2018-2032 (USD BILLION)
TABLE 64 Middle east Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 65 Middle east Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 66 Middle east Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 67 Africa Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 68 Africa Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 69 Africa Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
TABLE 70 Latin america Clinical genomics MARKET, BY Test Type, 2018-2032 (USD BILLION)
TABLE 71 Latin america Clinical genomics MARKET, BY METHOD, 2018-2032 (USD BILLION)
TABLE 72 Latin america Clinical genomics MARKET, BY END USER, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 Research Process
FIGURE 2 Market Structure for the Global Clinical genomics Market
FIGURE 3 Market Dynamics for the Global Clinical genomics Market
FIGURE 4 Global Clinical genomics Market, Share (%), BY Test Type, 2022
FIGURE 5 Global Clinical genomics Market, Share (%), BY METHOD, 2022
FIGURE 6 Global Clinical genomics Market, Share (%), BY END USER, 2022
FIGURE 7 Global Clinical genomics Market, Share (%), by Region, 2022
FIGURE 8 north AMERICA: Clinical genomics MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 Europe: Clinical genomics MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 Asia-Pacific: Clinical genomics MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 Rest of the world: Clinical genomics MARKET, SHARE (%), BY REGION, 2022
FIGURE 12 Global Clinical genomics Market: Company Share Analysis, 2022 (%)
FIGURE 13 Clinical genomics marketare Quest Diagnostics Incorporated (U.S.).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 Clinical genomics marketare Quest Diagnostics Incorporated (U.S.).: SWOT ANALYSIS
FIGURE 15 Eurofins Scientific SE (Luxembourg): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 Eurofins Scientific SE (Luxembourg): SWOT ANALYSIS
FIGURE 17 Illumina, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 Illumina, Inc. (U.S.): SWOT ANALYSIS
FIGURE 19 PerkinElmer, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 PerkinElmer, Inc. (U.S.): SWOT ANALYSIS
FIGURE 21 NeoGenomics Inc. (U.S.).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 NeoGenomics Inc. (U.S.).: SWOT ANALYSIS
FIGURE 23 FOUNDATION MEDICINE, INC. (U.S.).: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 FOUNDATION MEDICINE, INC. (U.S.).: SWOT ANALYSIS
FIGURE 25 Rosetta Genomics Ltd. (Israel): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 Rosetta Genomics Ltd. (Israel): SWOT ANALYSIS
FIGURE 27 Invitae Corporation (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 Invitae Corporation (U.S.): SWOT ANALYSIS
FIGURE 29 Myriad Genetics, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 Myriad Genetics, Inc. (U.S.): SWOT ANALYSIS
FIGURE 31 Natera, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 Natera, Inc. (U.S.): SWOT ANALYSIS
FIGURE 33 Genomic Health, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 Genomic Health, Inc. (U.S.): SWOT ANALYSIS
FIGURE 35 OPKO Health, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 36 OPKO Health, Inc. (U.S.): SWOT ANALYSIS
FIGURE 37 Centogene AG (Germany): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 38 Centogene AG (Germany): SWOT ANALYSIS
FIGURE 39 Clinical Genomics Pty Ltd. (Australia): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 40 Clinical Genomics Pty Ltd. (Australia): SWOT ANALYSIS
FIGURE 41 23andMe, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 42 23andMe, Inc. (U.S.): SWOT ANALYSIS
FIGURE 43 Iverson Genetic Diagnostics, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 44 Iverson Genetic Diagnostics, Inc. (U.S.): SWOT ANALYSIS
FIGURE 45 Veritas Genetics (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 46 Veritas Genetics (U.S.): SWOT ANALYSIS
FIGURE 47 Gene by Gene, Ltd. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 48 Gene by Gene, Ltd. (U.S.): SWOT ANALYSIS
FIGURE 49 GenomeDx Biosciences, Inc. (Canada): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 50 GenomeDx Biosciences, Inc. (Canada): SWOT ANALYSIS
FIGURE 51 MedGenome (India): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 52 MedGenome (India): SWOT ANALYSIS
FIGURE 53 Strand Life Sciences Pvt. Ltd. (India): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 54 Strand Life Sciences Pvt. Ltd. (India): SWOT ANALYSIS
FIGURE 55 Beijing Genomics Institute (BGI) (China): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 56 Beijing Genomics Institute (BGI) (China): SWOT ANALYSIS
FIGURE 57 Retrogen, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 58 Retrogen, Inc. (U.S.): SWOT ANALYSIS
FIGURE 59 Personalis, Inc. (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 60 Personalis, Inc. (U.S.): SWOT ANALYSIS
FIGURE 61 PathGroup (U.S.): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 62 PathGroup (U.S.): SWOT ANALYSIS
